Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/1998

01-08-1998 | ORIGINAL ARTICLE

Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

Authors: Kiyoshi Takasuna, Takehiro Hagiwara, Masaaki Hirohashi, Michiyuki Kato, Mamoru Nomura, Eiichi Nagai, Tsuyoshi Yokoi, Tetsuya Kamataki

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1998

Login to get access
Metadata
Title
Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats
Authors
Kiyoshi Takasuna
Takehiro Hagiwara
Masaaki Hirohashi
Michiyuki Kato
Mamoru Nomura
Eiichi Nagai
Tsuyoshi Yokoi
Tetsuya Kamataki
Publication date
01-08-1998
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1998
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050818

Other articles of this Issue 4/1998

Cancer Chemotherapy and Pharmacology 4/1998 Go to the issue

ORIGINAL ARTICLE

Fluorescence methods to assess multidrug resistance in individual cells

ORIGINAL ARTICLE

Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection

CLINICAL TRIAL REPORT

Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy

ORIGINAL ARTICLE

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

ORIGINAL ARTICLE

Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine

ORIGINAL ARTICLE

A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits